Eton Pharmaceuticals, Inc.

Fundamentals7.0
Price Action7.0
News Sentiment0.0
AI Rating
7.0

Key Drivers

  • Margin Expansion
  • Cash Flow Strength
  • Rich Valuation

AI
AI Summary

7.0

ETON now looks like a cash-generating commercial execution story—not a distressed microcap—with Q1 proving sales are translating into margin expansion and free cash flow, but the stock already prices in much of that progress, so the key tradeoff is continued launch execution versus valuation compression if momentum slows.

ExecutionMomentum
ValuationRisk
RareDisease‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Margin Expansion
  • Cash Flow Strength
  • Rich Valuation

ETON posted a strong quarterly turnaround with higher margins and solid cash flow, but elevated leverage, tighter liquidity, and a demanding valuation temper the investment case.

turnaround
overvalued

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Strong breakout
  • Higher highs
  • Overbought rally

ETON has stayed in a strong last month uptrend, breaking prior highs to $37.50, but the rapid near one-way advance now looks short-term overbought and vulnerable to a pullback toward $35.70-$36.20.

bullish
overbought
Support Level: $35.70-$36.20
Resistance Level: $37.50

Rapid rally from $27.61 to $37.50 suggests short-term volatility risk

Sentiment & News

0.0